Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CD40 activation as potential tool in malignant neoplasms.

Alessandro Ottaiano1, Carmela Pisano, Anna De Chiara

  • 1Division of Medical Oncology B, National Cancer Institute G Pascale, Naples, Italy. ale.otto@libero.it

Tumori
|December 19, 2002
PubMed
Summary

CD40 activation shows promise for treating B-cell malignancies and solid tumors by inducing apoptosis and stimulating immune responses. However, its precise role in cancer development requires further investigation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrated Histopathologic and Targeted Genomic Characterization of Gastric Adenocarcinomas with Yolk Sac Tumor Differentiation.

International journal of molecular sciences·2026
Same author

Non-invasive cell-free DNA-based approach for the diagnosis of aneuploidies in spontaneous abortion.

Fetal diagnosis and therapy·2026
Same author

Real-World Analysis of Metastatic Renal Cell Carcinoma Patients Treated with Pembrolizumab Plus Axitinib: Evidence from the Campania Oncology Network.

Current oncology (Toronto, Ont.)·2026
Same author

Treatment-aware deep learning enables counterfactual prediction of individual benefit from PARP inhibitors in ovarian cancer.

NPJ digital medicine·2026
Same author

Real-world outcomes of second-line pembrolizumab in urothelial carcinoma: a multicenter analysis from the Campania Oncological Network (ROC).

BMC cancer·2026
Same author

Oligometastatic versus polymetastatic colon cancer: functional and genomic determinants of divergent metastatic trajectories.

Exploration of targeted anti-tumor therapy·2026

Area of Science:

  • Oncology
  • Immunology

Background:

  • CD40 is a cell surface molecule found on B-cell malignancies and solid tumors.
  • It mediates apoptosis and immune responses, making it a potential target for cancer therapy.

Purpose of the Study:

  • To review the involvement of CD40 in tumors.
  • To discuss the rationale for CD40-activation-based therapies in antitumor protocols.

Main Methods:

  • A Medline review of published papers on CD40 activation in cancer therapy.

Main Results:

  • CD40 activation promotes tumor cell apoptosis and enhances tumor-specific T-cell responses.
  • Preclinical studies with CD40 ligand (CD40L) and anti-CD40 antibodies show tumor inhibition and immune stimulation.
  • CD40 expression in melanoma and lung cancer may have negative prognostic value; its upregulation in tumor vessels suggests a role in angiogenesis.

Related Experiment Videos

Conclusions:

  • CD40 activation is a promising target for hematological malignancies and solid tumors.
  • The exact functional role of CD40 in cancer development remains unclear and debated.